Stay updated with breaking news from Let Dosing Decision Software. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.
The U.S. Food and Drug Administration (FDA) has granted clearance to Beta Bionics Inc. for the company’s Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for use by people ages six years and older with type 1 diabetes.
The FDA has cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for persons 6 years of age and older with type 1 diabetes.
Announced by the US FDA on May 19, 2023, the clearance of the iLet ACE Pump and the iLet Dosing Decision Software, when combined with a compatible CGM, will form the iLet Bionic Pancreas.
/PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years...